The company's original tertiary target for the SCiStar study, after observing the safety and activity
of AST - OPC1, was that 45 - 50 %
of study subjects would recover at least 2 motor levels on at least one side at 12 months, which is approximately double the
rate of spontaneous recovery expected based on a similarly matched population and published literature.